CTN Accepted for SymBio’s Japan Phase 1 Trial of Rigosertib (SyB L-1101)

News   Sep 27, 2012

 
CTN Accepted for SymBio’s Japan Phase 1 Trial of Rigosertib (SyB L-1101)
 
 
 
FURTHER INFORMATION
 
 
 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE